JP2018524001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524001A5 JP2018524001A5 JP2018500423A JP2018500423A JP2018524001A5 JP 2018524001 A5 JP2018524001 A5 JP 2018524001A5 JP 2018500423 A JP2018500423 A JP 2018500423A JP 2018500423 A JP2018500423 A JP 2018500423A JP 2018524001 A5 JP2018524001 A5 JP 2018524001A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence represented
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 88
- 239000012634 fragment Substances 0.000 claims 24
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 8
- 239000013599 cloning vector Substances 0.000 claims 5
- 208000034799 Tauopathies Diseases 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15175522.0 | 2015-07-06 | ||
| EP15175522 | 2015-07-06 | ||
| PCT/EP2016/065813 WO2017005734A1 (en) | 2015-07-06 | 2016-07-05 | Tau-binding antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019220807A Division JP7100008B2 (ja) | 2015-07-06 | 2019-12-06 | Ｔａｕ結合抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524001A JP2018524001A (ja) | 2018-08-30 |
| JP2018524001A5 true JP2018524001A5 (enExample) | 2019-09-12 |
| JP6630426B2 JP6630426B2 (ja) | 2020-01-15 |
Family
ID=53524640
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500423A Active JP6630426B2 (ja) | 2015-07-06 | 2016-07-05 | Ｔａｕ結合抗体 |
| JP2019220807A Active JP7100008B2 (ja) | 2015-07-06 | 2019-12-06 | Ｔａｕ結合抗体 |
| JP2022105415A Active JP7413448B2 (ja) | 2015-07-06 | 2022-06-30 | Ｔａｕ結合抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019220807A Active JP7100008B2 (ja) | 2015-07-06 | 2019-12-06 | Ｔａｕ結合抗体 |
| JP2022105415A Active JP7413448B2 (ja) | 2015-07-06 | 2022-06-30 | Ｔａｕ結合抗体 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10287343B2 (enExample) |
| EP (1) | EP3319983B1 (enExample) |
| JP (3) | JP6630426B2 (enExample) |
| KR (2) | KR102770650B1 (enExample) |
| CN (1) | CN107849104B (enExample) |
| AR (1) | AR105267A1 (enExample) |
| AU (1) | AU2016289755C1 (enExample) |
| CA (1) | CA2991451A1 (enExample) |
| CL (1) | CL2018000043A1 (enExample) |
| CO (1) | CO2017012971A2 (enExample) |
| EA (1) | EA037092B1 (enExample) |
| EC (1) | ECSP18000887A (enExample) |
| IL (1) | IL256685B (enExample) |
| MA (2) | MA41670A1 (enExample) |
| MX (1) | MX2017015817A (enExample) |
| MY (1) | MY193677A (enExample) |
| PE (1) | PE20180481A1 (enExample) |
| PH (1) | PH12017502207B1 (enExample) |
| SG (1) | SG10202010735PA (enExample) |
| SM (1) | SMT202600068T1 (enExample) |
| TN (1) | TN2017000539A1 (enExample) |
| TW (1) | TWI745295B (enExample) |
| UA (1) | UA124616C2 (enExample) |
| UY (1) | UY36773A (enExample) |
| WO (1) | WO2017005734A1 (enExample) |
| ZA (1) | ZA201800027B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA126272C2 (uk) | 2015-06-05 | 2022-09-14 | Дженентек, Інк. | Антитіло проти тау-білка та спосіб його застосування |
| MA41670A1 (fr) | 2015-07-06 | 2018-05-31 | Ucb Biopharma Sprl | Anticorps se liant a tau |
| TN2017000543A1 (en) | 2015-07-06 | 2019-04-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| MX2019006334A (es) | 2016-12-07 | 2019-08-01 | Genentech Inc | Anticuerpos antitau y métodos de uso. |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP2020508054A (ja) | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 抗タウ抗体及びその使用方法 |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| UA129617C2 (uk) | 2017-10-16 | 2025-06-18 | Еісаі Р Енд Д Менеджмент Ко., Лтд. | Антитіло до тау та його застосування |
| US12509505B2 (en) | 2018-12-13 | 2025-12-30 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Anti Tau SVQIVYKPV epitope single domain antibody |
| CA3147548A1 (en) * | 2019-08-13 | 2021-02-18 | Randall Bateman | Methods to detect mtbr tau isoforms and use thereof |
| CA3167317C (en) | 2020-02-12 | 2025-05-27 | Eli Lilly And Company | CRYSTALLIZATION OF ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS |
| US20230265175A1 (en) | 2020-06-25 | 2023-08-24 | Merck Sharp & Dohme Llc | High affinity antibodies targeting tau phosphorylated at serine 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| IL320461A (en) * | 2022-11-14 | 2025-06-01 | Washington University St Louis | Methods for detecting MTBR-CSF Tau and its uses |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025171285A1 (en) * | 2024-02-09 | 2025-08-14 | University Of Notre Dame Du Lac | Tau proteomimetics |
| WO2025196217A1 (en) | 2024-03-21 | 2025-09-25 | UCB Biopharma SRL | Treatment of tauopathies with tau-binding antibodies |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| AU2004253738A1 (en) | 2003-07-01 | 2005-01-13 | Ucb Pharma S.A. | Modified antibody Fab fragments |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| CN1721437A (zh) * | 2004-07-13 | 2006-01-18 | 中南大学 | 一种与Tau蛋白相关的多肽抗原及抗体 |
| EP2500352A1 (en) | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| JP5592792B2 (ja) | 2007-09-26 | 2014-09-17 | ユセベ ファルマ ソシエテ アノニム | 二重特異性抗体の融合体 |
| CN101307108B (zh) * | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途 |
| LT2334705T (lt) | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | Biologiniai produktai |
| EP2346906A4 (en) | 2008-10-15 | 2013-04-24 | Angiochem Inc | CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE |
| JP5759379B2 (ja) | 2008-12-05 | 2015-08-05 | アンジオケム インコーポレーテッド | ニューロテンシンまたはニューロテンシンアナログおよびその使用 |
| US20110288009A1 (en) | 2008-12-05 | 2011-11-24 | Angiochem Inc. | Leptin and leptin analog conjugates and uses thereof |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
| US20120277158A1 (en) | 2009-10-06 | 2012-11-01 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
| EP2625198B1 (en) | 2010-10-07 | 2015-07-22 | AC Immune S.A. | Antibodies recognising phospho-tau |
| US8940272B2 (en) * | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| SG10201912964PA (en) | 2011-09-19 | 2020-02-27 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| US20140294724A1 (en) * | 2011-10-24 | 2014-10-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
| SI2776466T1 (sl) | 2011-11-11 | 2017-12-29 | Ucb Biopharma Sprl | Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti |
| DK2794654T3 (da) | 2011-12-20 | 2019-08-05 | Janssen Biotech Inc | Anti-phf-tau-antistoffer og deres anvendelser |
| SG10201913370PA (en) * | 2012-07-03 | 2020-03-30 | Univ Washington | Antibodies to tau |
| SI2885010T1 (sl) | 2012-08-16 | 2020-07-31 | Ipierian, Inc. | Metode zdravljenja tauopatije |
| BR112015014751A8 (pt) | 2012-12-21 | 2018-01-16 | Biogen Int Neuroscience Gmbh | anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos. |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| MA41670A1 (fr) | 2015-07-06 | 2018-05-31 | Ucb Biopharma Sprl | Anticorps se liant a tau |
| TN2017000543A1 (en) | 2015-07-06 | 2019-04-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
-
2016
- 2016-07-05 MA MA41670A patent/MA41670A1/fr unknown
- 2016-07-05 AU AU2016289755A patent/AU2016289755C1/en active Active
- 2016-07-05 UA UAA201711739A patent/UA124616C2/uk unknown
- 2016-07-05 PE PE2017002750A patent/PE20180481A1/es unknown
- 2016-07-05 CA CA2991451A patent/CA2991451A1/en active Pending
- 2016-07-05 KR KR1020187003689A patent/KR102770650B1/ko active Active
- 2016-07-05 MX MX2017015817A patent/MX2017015817A/es unknown
- 2016-07-05 SG SG10202010735PA patent/SG10202010735PA/en unknown
- 2016-07-05 MA MA042377A patent/MA42377A/fr unknown
- 2016-07-05 KR KR1020257004988A patent/KR20250027278A/ko active Pending
- 2016-07-05 EA EA201890172A patent/EA037092B1/ru not_active IP Right Cessation
- 2016-07-05 EP EP16734676.6A patent/EP3319983B1/en active Active
- 2016-07-05 JP JP2018500423A patent/JP6630426B2/ja active Active
- 2016-07-05 CN CN201680039795.4A patent/CN107849104B/zh active Active
- 2016-07-05 WO PCT/EP2016/065813 patent/WO2017005734A1/en not_active Ceased
- 2016-07-05 SM SM20260068T patent/SMT202600068T1/it unknown
- 2016-07-05 MY MYPI2018700043A patent/MY193677A/en unknown
- 2016-07-05 PH PH1/2017/502207A patent/PH12017502207B1/en unknown
- 2016-07-05 US US15/742,087 patent/US10287343B2/en active Active
- 2016-07-05 TN TNP/2017/000539A patent/TN2017000539A1/en unknown
- 2016-07-06 AR ARP160102045A patent/AR105267A1/es unknown
- 2016-07-06 UY UY0001036773A patent/UY36773A/es not_active Application Discontinuation
- 2016-07-06 TW TW105121455A patent/TWI745295B/zh active
-
2017
- 2017-12-18 CO CONC2017/0012971A patent/CO2017012971A2/es unknown
-
2018
- 2018-01-01 IL IL256685A patent/IL256685B/en unknown
- 2018-01-03 ZA ZA2018/00027A patent/ZA201800027B/en unknown
- 2018-01-05 CL CL2018000043A patent/CL2018000043A1/es unknown
- 2018-01-05 EC ECIEPI2018887A patent/ECSP18000887A/es unknown
-
2019
- 2019-05-13 US US16/409,945 patent/US10889640B2/en active Active
- 2019-12-06 JP JP2019220807A patent/JP7100008B2/ja active Active
-
2020
- 2020-12-29 US US17/136,189 patent/US11732034B2/en active Active
-
2022
- 2022-06-30 JP JP2022105415A patent/JP7413448B2/ja active Active
-
2023
- 2023-06-30 US US18/344,945 patent/US20230416350A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524001A5 (enExample) | ||
| JP2020513804A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| JP2020122013A5 (enExample) | ||
| JP2020504101A5 (enExample) | ||
| JP2018504105A5 (enExample) | ||
| RU2019120720A (ru) | Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином | |
| JP2010502207A5 (enExample) | ||
| JP2018516853A5 (enExample) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| WO2017009308A3 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| JP2019500007A5 (enExample) | ||
| JP2011528901A5 (enExample) | ||
| PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| JP2016536322A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| JP2010506596A5 (enExample) | ||
| JP2018505681A5 (enExample) | ||
| EA033433B1 (ru) | Антитела к tau и их применение | |
| PE20180481A1 (es) | Anticuerpos de union a tau | |
| JP2016516400A5 (enExample) | ||
| JP2015525211A5 (enExample) | ||
| FI3390451T3 (fi) | Kaninisoidut ihmisen vasta-aineet ihmisen ja koiraeläimen il-4r alfaa kohtaan | |
| EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr |